These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 10819579)

  • 61. Induction of T-cell antitumor immunity and protection against tumor growth by secretion of soluble human CD70 molecules.
    Cormary C; Gonzalez R; Faye JC; Favre G; Tilkin-Mariamé AF
    Cancer Gene Ther; 2004 Jul; 11(7):497-507. PubMed ID: 15153937
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effective anti-tumor immunity induced in mice by a two-step vaccination protocol.
    Martino A; Vismara D; Cicconi R; Delpino A; Ivanyi J; Colizzi V; Cassol M; Fraziano M; Piselli P
    In Vivo; 2001; 15(5):425-8. PubMed ID: 11695241
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Trafficking of 'immune' CD4(+)/CD8(+)T-lymphocytes into the RENCA tumour microcirculation in vivo in mice.
    Ali SA; Rees RC; Anderson DQ; Reed MW; Goepel JR; Brown NJ
    Br J Cancer; 2000 Oct; 83(8):1061-8. PubMed ID: 10993655
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Therapy-induced antitumor vaccination by targeting tumor necrosis factor alpha to tumor vessels in combination with melphalan.
    Mortara L; Balza E; Sassi F; Castellani P; Carnemolla B; De Lerma Barbaro A; Fossati S; Tosi G; Accolla RS; Borsi L
    Eur J Immunol; 2007 Dec; 37(12):3381-92. PubMed ID: 18022863
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Injection of IL-12 gene-transduced dendritic cells into mouse liver tumor lesions activates both innate and acquired immunity.
    Tatsumi T; Takehara T; Yamaguchi S; Sasakawa A; Miyagi T; Jinushi M; Sakamori R; Kohga K; Uemura A; Ohkawa K; Storkus WJ; Hayashi N
    Gene Ther; 2007 Jun; 14(11):863-71. PubMed ID: 17344900
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Intratumoral delivery of IL-18 naked DNA induces T-cell activation and Th1 response in a mouse hepatic cancer model.
    Chang CY; Lee J; Kim EY; Park HJ; Kwon CH; Joh JW; Kim SJ
    BMC Cancer; 2007 May; 7():87. PubMed ID: 17519043
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma.
    Kumano M; Hara I; Furukawa J; Oniki S; Nagai H; Miyake H; Fujisawa M
    J Urol; 2007 Oct; 178(4 Pt 1):1504-9. PubMed ID: 17707061
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Combinational immunotherapy for established tumors with engineered tumor vaccines and adenovirus-mediated gene transfer.
    Xiang J; Chen Y; Moyana T
    Cancer Gene Ther; 2000 Jul; 7(7):1023-33. PubMed ID: 10917205
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Local release of interleukin-10 by transfected mouse adenocarcinoma cells exhibits pro- and anti-inflammatory activity and results in a delayed tumor rejection.
    Di Carlo E; Coletti A; Modesti A; Giovarelli M; Forni G; Musiani P
    Eur Cytokine Netw; 1998 Mar; 9(1):61-8. PubMed ID: 9613679
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Expression of interleukins-23 and 27 leads to successful gene therapy of hepatocellular carcinoma.
    Hu P; Hu HD; Chen M; Peng ML; Tang L; Tang KF; Matsui M; Belladonna ML; Yoshimoto T; Zhang DZ; Xiang R; Ren H
    Mol Immunol; 2009 May; 46(8-9):1654-62. PubMed ID: 19299021
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Herpes simplex virus (HSV) amplicon-mediated codelivery of secondary lymphoid tissue chemokine and CD40L results in augmented antitumor activity.
    Tolba KA; Bowers WJ; Muller J; Housekneckt V; Giuliano RE; Federoff HJ; Rosenblatt JD
    Cancer Res; 2002 Nov; 62(22):6545-51. PubMed ID: 12438249
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Immunological responsiveness to interleukin-2-producing brain tumors can be restored by concurrent subcutaneous transplantation of the same tumors.
    Iwadate Y; Tagawa M; Namba H; Oga M; Kawamura K; Tasaki K; Sakiyama S; Yamaura A
    Cancer Gene Ther; 2000 Sep; 7(9):1263-9. PubMed ID: 11023199
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Activation of tumor-specific CD8+ T Cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy.
    VanOosten RL; Griffith TS
    Cancer Res; 2007 Dec; 67(24):11980-90. PubMed ID: 18089829
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Secretion of interleukin-10 from murine colon carcinoma cells suppresses systemic antitumor immunity and impairs protective immunity induced against the tumors.
    Kawamura K; Bahar R; Natsume W; Sakiyama S; Tagawa M
    Cancer Gene Ther; 2002 Jan; 9(1):109-15. PubMed ID: 11916240
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effectiveness of combined interleukin 2 and B7.1 vaccination strategy is dependent on the sequence and order: a liposome-mediated gene therapy treatment for bladder cancer.
    Larchian WA; Horiguchi Y; Nair SK; Fair WR; Heston WD; Gilboa E
    Clin Cancer Res; 2000 Jul; 6(7):2913-20. PubMed ID: 10914741
    [TBL] [Abstract][Full Text] [Related]  

  • 76. IL-2 gene delivery within an established murine tumor causes its regression without proliferation of preexisting antitumor-specific CTL.
    Levraud JP; Duffour MT; Cordier L; Perricaudet M; Haddada H; Kourilsky P
    J Immunol; 1997 Apr; 158(7):3335-43. PubMed ID: 9120291
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Induction of persistent tumor-protective immunity in mice cured of established colon carcinoma metastases.
    Xiang R; Lode HN; Dreier T; Gillies SD; Reisfeld RA
    Cancer Res; 1998 Sep; 58(17):3918-25. PubMed ID: 9731503
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Interleukin-18 gene transfer increases antitumor effects of suicide gene therapy through efficient induction of antitumor immunity.
    Ju DW; Yang Y; Tao Q; Song WG; He L; Chen G; Gu S; Ting CC; Cao X
    Gene Ther; 2000 Oct; 7(19):1672-9. PubMed ID: 11083476
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Melanoma differentiation-associated gene-7 (mda-7)/interleukin (IL)-24 induces anticancer immunity in a syngeneic murine model.
    Miyahara R; Banerjee S; Kawano K; Efferson C; Tsuda N; Miyahara Y; Ioannides CG; Chada S; Ramesh R
    Cancer Gene Ther; 2006 Aug; 13(8):753-61. PubMed ID: 16543916
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Local IL-4 delivery enhances immune reactivity to murine tumors: gene therapy in combination with IL-2.
    Pippin BA; Rosenstein M; Jacob WF; Chiang Y; Lotze MT
    Cancer Gene Ther; 1994 Mar; 1(1):35-42. PubMed ID: 7621236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.